Papers

2

Total Citations

52

H-Index

2

About

Dr. Sumi Dey is a leading urologic oncologist whose research focuses on optimizing surgical and perioperative outcomes for patients with renal cell carcinoma and complex genitourinary malignancies. Her most impactful work investigates the use of neoadjuvant targeted therapy, demonstrating that sunitinib can significantly reduce the size of inferior vena caval tumor thrombi, thereby facilitating safer surgical resection and improving oncologic outcomes. This multicenter comparative analysis, cited 41 times, has helped reshape treatment protocols for advanced kidney cancer. Dr. Dey has also made important contributions to the debate between robotic and open surgical approaches, particularly for patients with pre-existing chronic kidney disease. Her multicenter study comparing functional outcomes of robotic versus open partial nephrectomy (11 citations) provides critical evidence that robotic surgery can preserve renal function without compromising oncologic safety in this vulnerable population. Through these studies, Dr. Dey has advanced the integration of systemic therapies with minimally invasive surgical techniques, ultimately improving both survival and quality of life for patients facing aggressive kidney cancers.

Research Focus

Key Achievements

2
H-Index
2
Papers
52
Total Citations
26
Avg Citations/Paper
🏆 Most Cited Paper
Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis
41 citations · 2019
📈 Most Prolific Year: 2019 (1 Papers)
🤝 Key Collaborators: 27
🏛 Institutions: Spectrum Health, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago